Clinicopathological Significance of Cathepsin D Expression in Gastric Adenocarcinoma

Objective: An estrogen-regulated lysosomal protease, cathepsin D, has been detected in a variety of tissues. This proteinase has been described as closely associated with tumor progression and metastasis in malignant tumors. The purpose of this study was to determine the clinicopathological and prognostic significance of cathepsin D expression in gastric adenocarcinoma. Methods: In a consecutive series of 478 patients with gastric carcinoma (median follow-up period: 93 months, range: 1–285 months), cathepsin D expression in tumors was quantitatively analyzed with immunohistochemistry using a monoclonal antibody against cathepsin D (clone: 1C11). The percentage of cathepsin-D-positive cancer cells (the CD index) was calculated. In addition, the amount of cathepsin-D-positive stromal cells was evaluated; three grades (high, intermediate, and low) were used for the classification. Results: The mean CD index of 478 tumors was 12.8% (range: 0–100%, median: 8%). The mean CD index of diffuse-type gastric carcinomas (14.9%) was significantly higher than that of intestinal-type carcinomas (10.1%, p < 0.0001). Cathepsin D expression of cancer cells was significantly associated with the depth of tumor invasion in both types. The percentage of tumors with high cathepsin D expression in stromal cells was significantly higher in well-differentiated tumors (25.5%) than in moderately differentiated (12.8%) or in poorly differentiated tumors (19.1%). Cathepsin D expression of stromal cells was significantly associated with the depth of tumor invasion in the intestinal type, in contrast to the diffuse type. Highly expressed cathepsin D in cancer cells was associated with a poor prognosis in both types of carcinoma, but in stromal cells highly expressed cathepsin D was associated to a poor prognosis in the intestinal type only. Conclusion: These results indicate that cathepsin D expression in cancer cells may play an important role in tumor progression in diffuse-type gastric carcinoma, whereas in the intestinal type of carcinoma, cathepsin D expression in stromal cells may play an important role in tumor progression.

[1]  K. Haruma,et al.  Predictive value of cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer. , 2000, Oncology reports.

[2]  T. Fujimori,et al.  Immunohistochemical localization of cathepsin D in colorectal tumors , 2000, Diseases of the colon and rectum.

[3]  A. Scorilas,et al.  Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  R. Chirino,et al.  Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer , 1999, British Journal of Cancer.

[5]  Hsiu‐Po Wang,et al.  Loss of pS2 Protein Expression Is an Early Event of Intestinal‐type Gastric Cancer , 1998, Japanese journal of cancer research : Gann.

[6]  E. Ioachim,et al.  Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer , 1997, Virchows Archiv.

[7]  A. Lazaris,et al.  Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma , 1997, Journal of surgical oncology.

[8]  H. Allgayer,et al.  An immunohistochemical assessment of cathepsin D in gastric carcinoma , 1997, Cancer.

[9]  M. Sobrinho-Simões,et al.  pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study. , 1996, European journal of cancer.

[10]  A. Kaider,et al.  Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer. , 1996, British Journal of Cancer.

[11]  F. May,et al.  Cathepsin D and breast cancer. , 1996, European journal of cancer.

[12]  N. Gebbia,et al.  Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report. , 1995, Oncology.

[13]  A. Lazaris,et al.  Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarcinoma , 1995, Journal of surgical oncology.

[14]  J. Isola,et al.  Stromal cell cathepsin D expression and long-term survival in breast cancer. , 1995, British Journal of Cancer.

[15]  C. Benz,et al.  Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  F. Borchard,et al.  pS2 protein in gastric carcinoma and normal gastric mucosa: Association with clinicopathological parameters and patient survival , 1993, The Journal of pathology.

[17]  D. Potvin,et al.  Prognostic significance of cathepsin‐D expression in node‐positive breast carcinoma: An immunohistochemical study , 1993, International journal of cancer.

[18]  J. Kraimps,et al.  Estrogen receptors and cathepsin d in human thyroid tissue , 1993, Cancer.

[19]  K. Chang,et al.  Prognostic significance of immunohistochemical analysis of cathepsin D in low‐stage breast cancer , 1993, Cancer.

[20]  S. Leinster,et al.  Prognostic significance of cathepsin-D in patients with breast cancer. , 1993, British Journal of Cancer.

[21]  T. Visakorpi,et al.  Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Striker,et al.  Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. , 1992, The American journal of pathology.

[23]  M. Duffy,et al.  Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. , 1992, Clinical chemistry.

[24]  H. Rochefort,et al.  Biological and clinical significance of cathepsin D in breast cancer. , 1992, Acta oncologica.

[25]  松井 道宣.  Characterization of estrogen receptor in human gastric cancer , 1992 .

[26]  O. Kojima,et al.  Characterization of estrogen receptor in human gastric cancer , 1991, Cancer.

[27]  O. Kojima,et al.  Localization of estrogen receptors in gastric cancer using immunohistochemical staining of monoclonal antibody , 1991, Cancer.

[28]  P. Pujol,et al.  Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. , 1990, Oncogene.

[29]  T. Saku,et al.  Cathepsins D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. , 1990, Gut.

[30]  H. Rochefort,et al.  Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. , 1990, Cancer research.

[31]  H. Rochefort,et al.  Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. , 1989, Cancer research.

[32]  T. Salo,et al.  Proteolytic degradation of extracellular matrix in tumor invasion. , 1987, Biochimica et biophysica acta.

[33]  Marcel Garcia,et al.  Estrogen‐induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? , 1987, Journal of cellular biochemistry.

[34]  G. Asano,et al.  Estrogen and Progesterone Receptors in Gastric Cancer , 1986, Cancer.

[35]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.